Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
28-day inhaled CHF 6001 versus roflumilast and placebo in COPD (three-way crossover)
2012-001005-25Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tanimilast in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Started Jun 2012; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-001005-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001005-25.